EGFR and neoplasm: In the last decades, the introduction of targeted therapies has led to great progress in tumor response to treatment and patient survival in many cancer types, including sCRC, but only selected subgroups of patients within a given tumor type may benefit from these novel agents (e.g. anti-EGFR and anti-VEGF therapies) based on better responses to therapy and a significantly improved outcome [3].